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INTRODUCTION
Scientific research is a curious endeavour: on the one hand, we yearn for the certainty that we 
believe science can offer while on the other hand, we 
acknowledge the uncertainties inherent in “dealing with 
new phenomena at or beyond the boundaries of current 
knowledge” (Nature Medicine, 2001).
In thinking about what science and specifically 
scientific research at an academic institution such as 
Stellenbosch University means to me personally, I 
was finding it difficult to distil the essence of my own 
experience. During a conversation with my daughter 
Una, who was reading Looking for Alaska by John Greene, 
she introduced me to the phrase, “I go to seek a 
Great Perhaps”.1 This so perfectly articulated my own 
experience that I decided to use it as the title for this 
inaugural lecture.
Scientific research is concerned with questions; it is 
in essence a quest to understand how things work, a 
quest to make sense of life,2 a quest to find ‘the truth’ 
within an overwhelming labyrinth of data. It requires 
curiosity, “a capacity of pleasure in knowing”,3 restless 
inquiry in the pursuit of a particular knowledge. The 
image of a quest evoked by the word ‘seek’ in “I go to 
seek a Great Perhaps”, however, also conjures up images 
of mystery, the unknown, and troubles and tribulations 
to be overcome while promising prospects of marvels, 
wonders and delights to be discovered and a sense of 
awe to be experienced.
Most scientists are acutely aware of the fact that our 
knowledge is provisional, precariously awaiting the next 
discovery to render it obsolete, yet we learn to live with 
“approximate answers, possible beliefs and different 
degrees of certainty”, as so strikingly expressed by 
Richard Feynman (Robbins, 1999). We have to embrace 
doubt, ‘the Great Perhaps’, yet also endeavour to 
harness that doubt in seeking out the marvels, wonders 
and delights within our chosen fields. That promise is 
perhaps ultimately what motivates and inspires us.
For the last 25 years my quest has involved trying 
to grasp a little of the mystery of the marvellous 
structure4 of the signal transduction system whereby 
steroid receptors, such as the glucocorticoid receptor 
(GR) and the oestrogen receptor (ER), provoke a 
cellular or systemic effect. This quest to understand at 
a fundamental molecular level how specific compounds 
or physiological conditions elicit a specific response has 
been the driving force for my research, that and the 
promise of ‘marvels, wonders and delights’. This article 
will highlight some of our approximate understandings 
of the system and describe some of the small instances 
where ‘a perhaps’ has guided our endeavours. The 
‘Great Perhaps’ is still awaiting us. First, however, the 
steroid hormones and their signal transduction system 
should be briefly introduced. 
STEROID HORMONES
Most of us have heard of steroids; anabolic steroid use in sports is frequently reported in the news, 
and many of us are using steroidal drugs for inflammation 
or hormone replacement therapy (HRT). The term 
‘steroid’ describes both hormones endogenously 
produced by the body and artificially produced drugs 
that duplicate the action of the naturally occurring 
steroids. Steroid hormones belong to a class of chemical 
compounds known as steroids,5 which are lipid-like 
molecules synthesised and secreted by the adrenal 
glands, gonads (testes and ovaries) and placenta during 
pregnancy. These hormones may be divided into five 
groups: glucocorticoids, mineralocorticoids, androgens, 
oestrogens and progestogens (Table 1).
1. Although much doubt exists due to lack of documentation, these are generally thought to be the last words of François Rabelais 
(1483–1553), a major French Renaissance writer. 
2. Here I am referring to the property or quality that distinguishes living organisms from dead organisms, manifested in functions such as 
metabolism, growth, reproduction and response to stimuli or adaptation to the environment originating from within the organism (cf. the 
Online Merriam-Webster Dictionary (Life, s.a.)). 
3. As Ruskin put it. (Davies, 1888).
4. Adapted from a quote attributed to Einstein. The full quote reads as follows: “The important thing is not to stop questioning. Curiosity 
has its own reason for existing. One cannot help but be in awe when he contemplates the mysteries of eternity, of life, of the marvellous 
structure of reality. It is enough if one tries merely to comprehend a little of this mystery every day. Never lose a holy curiosity” (Miller, 
1955).
4Table 1: Classes of steroid hormones, endogenous and exogenous examples, and their 
functions and uses
Steroid hormone class Endogenous Exogenous (drugs)
Example Function Example Use






Mineralocorticoids Aldosterone Salt and water 
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Fludrocortisone Addison’s disease
















Progestogens Progesterone Maintains pregnancy MPAb and NETc HRT and 
contraception
aConjugated equine oestrogens; bmedroxyprogesterone acetate; cnorethindrone
VARIATIONS ON THE SAME THEME: 
STEROID HORMONE SIGNAL 
TRANSDUCTION
Steroid hormones can act as chemical messengers in a wide range of species and target tissues. They 
are transported in the blood from the tissues in which 
they are synthesised to target tissues where they will 
mediate their effects. Because of their lipophilic6 nature, 
steroid hormones in blood are bound to carrier proteins 
such as albumin (the most abundant protein in blood 
plasma that non-specifically binds lipophilic molecules 
with low affinity7) and the high-affinity carrier proteins, 
corticosteroid-binding globulin (CBG) and sex hormone-
binding globulin (SHBG) (Table 2). These carrier 
proteins not only act as facilitators of transport but also 
modulate the bioavailability of the steroid hormones as 
only the free, unbound fraction of a steroid hormone 
can transverse the cell membrane.8 For example, in 
blood, only 3.5% of cortisol is in the free, unbound form 
with the majority of the cortisol transported bound 
to CBG (90%) and a small amount transported bound 
to albumin (6.5%). Thus the bioavailability of the free, 
unbound fraction of cortisol may be modulated by 
the concentration of CBG in blood, and if CBG levels 
increase, the percentage free cortisol will decrease and 
vice versa.
Table 2: Classes of steroid hormones, their high-affinity carrier proteins and cognate receptors
Steroid hormone class Carrier proteins Receptor
Abbreviation
Glucocorticoids CBG Glucocorticoid receptor GR
Mineralocorticoids CBG Mineralocorticoid receptor MR
Androgens SHBG Androgen receptor AR
Oestrogens SHBG Oestrogen receptor ER
Progestogens CBG Progesterone receptor PR
................................
5. Steroids comprise a group of cyclical organic compounds whose basis is a characteristic arrangement of carbon atoms in a four-ring 
structure linked together to form three six-carbon rings followed by a five-carbon ring and an eight-carbon side chain on carbon 17.
6. ‘Lipophilic’ from the Greek for ‘fat loving’ refers to the propensity of a compound to dissolve in oils, lipids and nonpolar compounds. 
The axiom that like dissolves like generally holds true, and thus steroid hormones as lipophilic substances do not dissolve particularly well 
in plasma (the liquid component of blood), which is hydrophilic (water loving).
7. ‘Binding affinity’ refers to the tendency of a compound (ligand) to bind to a protein, which may be a carrier protein or a receptor. We can 
quantify this binding tendency by determining the equilibrium dissociation constant for binding (Kd), which informs us of the concentration 
of ligand required to half-saturate the protein. The smaller the value of Kd, the higher the binding affinity as less ligand is required to bind 
to half the binding sites.
5Table 2: Classes of steroid hormones, their high-affinity carrier proteins and cognate receptors
Steroid hormone class Carrier proteins Receptor
Abbreviation
Glucocorticoids CBG Glucocorticoid receptor GR
Mineralocorticoids CBG Mineralocorticoid receptor MR
Androgens SHBG Androgen receptor AR
Oestrogens SHBG Oestrogen receptor ER
Progestogens CBG Progesterone receptor PR
Having diffused across the cell membrane (Figure 1A, 
Step 1), steroid hormones bind specifically and with high 
affinity to their matching or cognate receptors (Table 2). 
These receptors are part of a larger family of 
receptors, the nuclear receptor (NR) superfamily, 
that act as ligand-activated transcription factors. This 
denotes that upon binding of a ligand (the specific 
steroid hormone), the cognate steroid hormone 
receptor is empowered to regulate the transcription9 of 
genes. This process, from ligand binding to regulation of 
transcription, is called the signal transduction pathway 
of steroid hormones. Although variations do occur, 
a central theme for the signal transduction pathway 
of steroid hormones is discernible and generally 
the individual steps involved in steroid signalling are 
sufficiently similar for a preliminary understanding. 
Specifically, the individual steps of steroid hormone signal 
transduction include binding of the steroid hormone 
to the cognate steroid receptor (Figure 1A, Step 2), 
which is tethered in the cytoplasm bound to chaperone 
molecules. Ligand binding results in a conformational 
change of the receptor, which allows for dissociation 
from the chaperone molecules, homodimerisation10 and 
translocation into the nucleus (Figure 1A, steps 2, 3 and 
4). Once in the nucleus, the activated NR homodimer 
binds to specific regions on DNA called nuclear receptor 
response elements (NREs), situated in the promoter11 
of steroid hormone-responsive genes (Figure 1A, Step 
5), and recruits coactivators and the basal transcription 
machinery, which initiates transcription of the gene 
(Figure 1A, Step 6). Variations on the central theme 
of the signal transduction pathway of steroid hormone 
receptors include binding of steroid receptor monomers 
to negative-response elements (Figure 1B), thereby 
preventing initiation of transcription. In addition, a 
tethering mechanism whereby a steroid receptor 
monomer binds to another transcription factor and in so 
doing either attenuates or potentiates the transcription 
Figure 1: The signal transduction pathway of steroid hormones. (A) The central theme of transactivation through binding of an NR dimer 
to an NRE, which results in transcription of the gene. Step 1: free, unbound steroid hormone (SH) diffuses across cell membrane; Step 2: 
binding of SH to NR, conformational change and dissociation of chaperone molecules; Step 3: dimerisation; Step 4: nuclear localisation; 
Step 5: binding of a ligand-activated, dimerised NR to an NRE in the promoter of a responsive gene; and Step 6: transactivation or initiation 
of transcription (indicated with a + sign). Variations on the theme include (B) binding of an NR monomer to a negative-response element 
(nNRE), which prevents transcription (indicated with a - sign), and (C) positive and (D) negative tethering whereby an NR monomer binds 
to another transcription factor (TF) already bound to the promoter, thereby potentiating or attenuating the response of the originally bound 
transcription factor.
................................
8. The cell membrane consists of a double layer of lipids, and thus the lipophilic steroid hormones, unbound to carrier proteins, can diffuse 
across the membrane into the cytoplasm of the cell.
9. Genes are transcribed to messenger RNA, which in turn is translated to form proteins. This process is often called the Central Dogma 
of Biology.
10. Dimerisation in this context involves a protein complex formed by two non-covalently bound steroid hormone receptors. A homodimer 
would be formed by the dimerisation of two identical bound steroid hormone receptors.
6elicited by the initial transcription factor is a common 
regulatory variation seen in the signal transduction 
pathway of steroid hormones (Figure 1C and D). 
THE DOUBLE-EDGED SWORD 
OF STEROID HORMONES: 
GLUCOCORTICOIDS AND 
OESTROGENS AS A CASE IN POINT
Steroid hormones are essential for the control of a plethora of regulatory systems in the human 
body. This is a finely balanced system, and over- or 
underproduction of these hormones can have serious 
health consequences, as can the use of exogenous 
hormones. As my group’s focus has mainly been on 
the signal transduction pathway of glucocorticoids and 
oestrogens, I will henceforth focus on these two steroid 
hormones. 
Glucocorticoids regulate a broad spectrum of 
physiologic functions essential for life and play a 
fundamental role in the maintenance of resting and 
stress-related homeostasis. Glucocorticoids act on 
nearly every tissue in the body and play a pivotal 
role in critical biologic processes, such as growth, 
reproduction, cognition, behaviour and maintenance of 
proper cardiovascular tone. In addition, they regulate 
the intermediary metabolism primarily through catabolic 
actions in the liver, muscle and adipose tissue, and 
influence substantially the quantity and quality of the 
inflammatory and immune responses (Busillo and 
Cidlowski, 2013). It is this last attribute that has resulted 
in their commercial exploitation. 
Glucocorticoid drugs are widely used and prescribed12 
as immunosuppressant and anti-inflammatory drugs 
in diseases such as asthma, arthritis and autoimmune 
diseases. Although amongst the most efficacious drugs 
to treat inflammation, their efficaciousness is a double-
edged sword as prolonged high-dose treatment can 
result in serious side effects such as glucocorticoid-
induced osteoporosis, metabolic syndrome (increased 
glucose production by the liver leading to hyperglycaemia 
and increased serum lipids or hyperlipidaemia), muscle 
wasting (atrophy) and glucocorticoid resistance (when 
patients no longer respond to therapy). 
Oestrogens are the female sex hormones and 
play an important role in the development of the 
reproductive tract and secondary sex characteristics 
and in reproductive behaviour. In addition, oestrogens 
maintain bone density and skin elasticity and protect 
against cardiovascular disease. However, because of 
their stimulating effect on growth and proliferation 
of certain cells, they are a risk factor for breast and 
endometrial cancer.13
Oestrogen levels in women decline at around 
50 years of age and menopause ensues. Menopausal 
symptoms include hot flashes, night sweats, sleeping 
problems, vaginal dryness and osteoporosis. HRT has 
been most effective in controlling menopausal symptoms, 
yet the double-edged sword of steroid hormones has 
also had repercussions in that HRT increases the risk 
for developing breast cancer.14 Most breast cancers 
are oestrogen dependent in that they contain the 
ER and signal transduction via this receptor results 
in proliferation of cancer cells. Selective oestrogen 
receptor modulators (SERMs), such as raloxifene and 
tamoxifen, which counteract the effects of oestrogen in 
the breast, are used as hormonal therapy in patients with 
ER-positive breast cancer (Jordan, McDaniel, Agboke 
and Maximov, 2014).
COMPOUND A: A GROWING TREE 
OF KNOWLEDGE
The story of Compound A (CpdA) illustrates my quest of ‘seeking a Great Perhaps’. It is a quest that started 
during my PhD research and has continued to date, a 
quest that has brought unimagined possibilities and 
glorious prospects. Like a growing tree of knowledge, 
each new shoot evolved from a tiny bud to a growth of 
novel possibilities and fresh avenues to explore.
................................
11. A promoter is a section of DNA that generally occurs upstream of a gene. The promoter is involved in regulating the transcription of 
the gene and is the site where transcription factors bind.
12. Advair Diskus from GlaxoSmithKline, a drug prescribed for the treatment of asthma, chronic bronchitis and chronic obstructive 
pulmonary disease, contains the synthetic glucocorticoid fluticasone propionate and is amongst the top 10 drugs by total sales and total 
prescriptions in the United States of America (Top 100 Most Prescribed, Top Selling Drugs. Medscape. May 13, 2014).
7The first bud: Cytochrome P450c11
Gannabos (Salsola tuberculatiformis Botschantzev) is a Karoo shrub that causes grootlamsiekte15 in sheep 
and contraception in rats (Figure 2A). When I joined 
the department in the 1990s, significant progress under 
the direction of Prof Kirsten van der Merwe had been 
made in unravelling the mechanism responsible for 
the actions of S. tuberculatiformis and in identifying the 
type of compound involved. Specifically, Proff Pieter 
and Amanda Swart had identified inhibition of adrenal 
cortisol biosynthesis as a potential site (the first perhaps) 
of action,16 had developed two useful bioassays for 
evaluation of activity17 and had produced an active but 
labile fraction, S2, from the shrub (Swart, Swart, Louw 
and van der Merwe, 2003). A putative structure of the 
active compound in the S2 fraction was proposed: a 
labile hydroxyphenyl aziridine precursor compound that 
could cyclise to form an aziridine (2-(4-hydroxyphenyl)-
1-methyl-aziridiniumchloride). In an attempt to produce 
a more stable analogue, Dr Schalk de Kock synthesised 
a whole series of hydroxyphenyl aziridine precursor 
compounds (compounds A to Z).
I evaluated the series of compounds for 
activity and established that the first in the 
series, CpdA (2-(4-acetoxyphenyl)-2-chloro-N-methyl-
ethylammonium chloride), had biological activity. The 
next step was to establish whether CpdA (Figure 2B) 
was a good analogue for the active compound(s) in the 
shrub S. tuberculatiformis and for the labile S2 fraction 
isolated from the shrub. Vaginal smears of nulliparous 
female Wistar rats18 that had been administered 
either S. tuberculatiformis (orally) or CpdA (orally and 
intraperitoneally) indicated equivalent contraceptive 
activity characterised by a significant decrease during 
Figure 2: S. tuberculatiformis Botschantzev (A) and CpdA (2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride) (B), an 
analogue of the active compound in the shrub
................................
13. Increased lifetime oestrogen burden, for example in women with early menarche and late menopause, is one on the strongest factors 
in risk of breast cancer in women. 
14. Recent large randomised clinical trials on HRT, such as the Women’s Health Initiative trial in the United States of America, and 
observational studies, such as the Million Women Study in the United Kingdom, have modified the risk-benefit perception of HRT, 
specifically regarding an increased risk of breast cancer and cardiovascular disease. The Endocrine Society statement of 2010 now 
recommends use of HRT with the lowest effective dose and for the shortest duration possible.
15. Grootlamsiekte is an Afrikaans term for a syndrome of prolonged gestation and foetal postmaturity first described amongst Karakul 
sheep feeding on S. tuberculatiformis and literally translates as ‘big lamb disease’.
16. Initiation of parturition in sheep had been shown to be dependent on a foetal surge in cortisol, and ablation of this surge would result 
in prolonged gestation. 
17. The first bioassay was based on the spectral and catalytic properties of cytochrome P450c11, the final enzyme involved in cortisol 
production, while the second bioassay involved a Pap smear (daily inspection of vaginal smears from female rats) to establish contraceptive 
properties.
8administration in the number of oestrus days per 16-day period from 4.00 for control rats to 2.92 and 2.33, respectively 
(Louw, Swart, de Kock and van der Merwe, 1997; Louw and Swart, 1999). The contraceptive effect was reversible, and 
on cessation of treatment, the oestrus cycle of the rats returned to that of the control rats. In addition, the P450c11 
spectral assay indicated that CpdA inhibited the final step in glucocorticoid synthesis in a manner similar to that of S2. 
Specifically, CpdA, like S2, elicited a Type II difference spectrum,19 indicative of the presence of a nitrogen moiety, and 
inhibited the Type I difference spectrum elicited by deoxycorticosterone, the natural substrate of cytochrome P450c11 
(Figure 3) (Louw et al., 1997; Louw, Allie, Swart and Swart, 2000; Swart et al., 2003). Comparison of CpdA’s inhibitory 
capacity with that of other well-known inhibitors of cytochrome P450c11, however, indicated that CpdA was not a 
particularly effective inhibitor (Louw, Swart and Allie, 2000).
The second bud: Corticosteroid-binding 
globulin
The spectral studies of the interaction of CpdA with cytochrome P450c11 were most challenging as the 
effects of CpdA on both the Type II and Type I spectral 
properties attenuated over time. The question that arose 
at this stage was, If CpdA was such a labile compound, 
how could it possibly mediate its effects physiologically? 
Prof Pieter Swart, my PhD promoter, suggested that 
perhaps a component in blood plasma stabilised CpdA. 
I investigated this possibility and indeed found that 
although CpdA’s inhibitory capacity was attenuated in 
buffer by 30 minutes, addition of rat or sheep plasma 
could stabilise the inhibitory activity of CpdA (Louw et 
al., 1997). Electrospray mass spectrometry confirmed 
our results by indicating that in buffer, the cyclisation of 
CpdA to its corresponding aziridine followed a similar 
time course to that of the attenuation of cytochrome 
Figure 3: The P450c11 bioassay. (A) Examples of cytochrome P450 Type I (bold solid line) and Type II (solid line) difference spectra. (B) 
Type I difference spectrum (bold solid line) of a sheep adrenal cytochrome P450 preparation induced by deoxycorticol (DOC) and Type II 
difference spectrum (solid line) induced by either S2 (B) or CpdA (C). Inhibition of DOC-induced Type I difference spectrum (bold dotted 
line) by either S2 (B) or CpdA (C) (Swart et al., 2003).
................................
18. Wistar albino rats, developed at the Wistar Institute in 1906 for use in basic biological and medical research, are notably the first rat 
strain developed to serve as a model organism. The oestrous cycle of the rat lasts four days on average and comprises distinct phases 
characterised by different cell types in vaginal smears (proestrus, oestrus, metestrus and diestrus). The classical Papanicolaou technique, 
developed by George Papanikolaou, is used to stain the vaginal smears and identify the cells. This is the same procedure used for cervical 
cancer screening in gynaecology (known as the Pap smear).
19. All cytochromes P450 have a heme iron in their active sites. Interaction of certain inhibitors or substrates with the heme iron in the 
active site gives rise to unique spectral properties. A Type I difference spectrum (absorbance maximum at 385–395 nm and absorbance 
minimum at 420 nm) is elicited by the natural substrate for the enzyme (e.g. deoxycorticosterone for P450c11) whereas a Type II 
difference spectrum (absorbance maximum at 430 nm and absorbance minimum at 390 nm) is often observed with ligands that contain a 
nitrogen moiety.
9P450c11 inhibition and that addition of sheep plasma 
could retard this cyclisation. Furthermore, the 
electrospray mass spectrometry results established that 
CpdA and not its corresponding aziridine was the active 
agent inhibiting cytochrome P450c11 activity. 
In serum or plasma, steroid hormones are either 
free in solution or bound to albumin, CBG and SHBG 
(Table 2). Thus we thought that perhaps these proteins 
could be involved in the stabilisation of CpdA’s activity 
in plasma. To test this hypothesis, we heated sheep 
plasma, which denatures CBG and SHBG but not 
albumin, and established that heated plasma abrogated 
the stabilising effect observed in native plasma (Louw et 
al., 1997). As rat plasma does not contain SHBG, CBG 
was selected for further investigation. Studies of rat 
and sheep plasma indicated that CpdA could displace 
endogenously bound glucocorticoids (cortisol in sheep 
or corticosterone in rats) but not progesterone from 
CBG, and concomitantly, a significant increase in free 
glucocorticoids but not progesterone was measured 
(Louw, Swart and Allie, 2000). In addition, we established 
that competitive inhibition of glucocorticoid binding 
occurred, which would suggest direct competition with 
the endogenous ligands, and that CpdA probably bound 
at the same ligand binding site on CBG (Louw, Swart and 
Allie, 2000).
Although the studies establishing that CpdA binds 
to and is stabilised by CBG in plasma answered the 
troublesome question of how such a labile compound 
could have a physiological effect, the results also raised 
the possibility that perhaps the contraceptive effects of 
CpdA were not mediated exclusively through inhibition 
of glucocorticoid synthesis (cytochrome P450c11 
inhibition), as previously thought. We were thus faced 
with two contrasting scenarios (Figure 4), both of which 
had been shown to elicit a contraceptive effect in rats:
1. The first scenario mimics adrenalectomy (removal 
of adrenal glands) in that glucocorticoid biosynthesis 
in the adrenal is inhibited by CpdA.
2. The second scenario mimics a state of chronic 
stress with increased free glucocorticoids in that 
CpdA displaces glucocorticoids from CBG with a 
concomitant rise in free glucocorticoid levels.
We postulated that Scenario 1 should result in a 
decrease in total and thus also free glucocorticoid levels 
and that this decrease in free glucocorticoid levels would 
attenuate the negative feedback of glucocorticoids 
on the synthesis of several other proteins, most 
notably adrenocorticotropic hormone (ACTH)20 
and CBG,21 resulting in their increased production. 
In contrast, Scenario 2 would result in an increase in 
free glucocorticoids with a concomitant decrease in 
ACTH and CBG due to increased negative feedback. 
Administration of S. tuberculatiformis and CpdA at a 
contraceptive dose resulted in a significant increase in 
free glucocorticoids and a decrease in ACTH and CBG 
levels (Louw and Swart, 1999). These results then favour 
the second scenario, which mimics stress and entails 
binding of S. tuberculatiformis and CpdA to CBG, thereby 
displacing endogenous glucocorticoids and resulting 
in an increase in free glucocorticoids that feedback 
negatively on, amongst others, the pituitary (site of 
ACTH synthesis) and liver (site of CBG synthesis). 
................................
20. ACTH is a hormone produced by the anterior pituitary and is part of the hypothalamic-pituitary-adrenal axis (HPA-axis). The HPA-
axis controls the secretion of glucocorticoids: stress activates the hypothalamus in the brain to secrete corticotropin-releasing factor 
(CRF), which activates the pituitary (a small gland near the base of the brain) to secrete ACTH that in turn activates the adrenal glands 
(situated above the kidneys) to secrete glucocorticoids. Glucocorticoids have a negative feedback effect on the hypothalamus and pituitary, 
decreasing the secretion of CRH and ACTH, respectively. This negative feedback system is a common motive in biology and is designed 
to limit the secretion of hormones.
21. CBG, synthesised in the liver, is regulated by glucocorticoids. CBG biosynthesis is stimulated during adrenalectomy and inhibited during 
exogenous glucocorticoid treatment.
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Stress, as exemplified by increased levels of free 
glucocorticoids, has been shown to profoundly suppress 
the reproductive system at multiple levels, including 
the hypothalamus, pituitary and gonads, and thus our 
results suggest that this scenario could account for the 
contraceptive mechanism of action of S. tuberculatiformis 
and CpdA. In addition, our results could also explain the 
syndrome of prolonged gestation in sheep. Parturition 
is sheep is accompanied by activation of the foetal 
HPA-axis (suggested to be due to the stress of foetal 
hypoglycaemia resulting from placental insufficiency at 
this late stage of gestation), resulting in a progressive 
prepartum surge in glucocorticoids and ACTH. Despite 
this, free glucocorticoid levels do not increase as the 
foetal liver increases production of CBG.22 In addition, 
local CBG production in the foetal pituitary attenuates 
the negative feedback on ACTH production. Taken 
together, these observations suggest that foetal CBG 
buffers the prepartum increase in glucocorticoids, 
thus contributing to continual HPA-axis signalling and 
ACTH production. Just before parturition, the free 
glucocorticoid levels rise significantly, presumably 
due to saturation of CBG by the continued surge in 
glucocorticoid production. These high levels of free 
glucocorticoids are required to activate an enzyme that 
reduces maternal progesterone to concentrations at 
which uterine activity is increased and labour ensues. 
Ingestion of S. tuberculatiformis during the last 50 days of 
gestation results in prolonged gestation, and we could 
perhaps suggest that displacement of glucocorticoids from 
CBG with a concomitant increase in free glucocorticoid 
levels could increase systemic CBG levels,23 thereby 
Figure 4: Schematic of the two possible scenarios that could explain the contraceptive effect of S. tuberculatiformis Botsch. or CpdA in 
rats. Diagram depicts the HPA-axis, which shows negative feedback (dashed arrows) by free glucocorticoids (GCs) and the liver, which 
synthesises CBG and is also under negative feedback from free GCs. The intensity of the dashed arrows reflects the strength of the negative 
feedback. In addition, for both scenarios, the effect on hormones (CRF, ACTH and GCs) and binding proteins (CBG) is indicated by ↓ if the 
levels decreased and by ↑ if the levels increased (Swart et al., 2003).
................................
22. The sheep foetal liver responds differently from the adult liver in that glucocorticoids stimulate rather than inhibit CBG production.
23. Interestingly, the dose of glucocorticoids required to increase foetal CBG production is lower that the dose required to initiate 
parturition.
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delaying the prepartum surge in free glucocorticoids 
required for parturition. Eventually, however, increased 
trophic drive from the hypothalamus will overcome 
these factors and parturition, albeit delayed, will occur.24 
The above discussion is speculative at present and 
would require further research to establish a definitive 
mechanism.
The third bud: The glucocorticoid receptor
Having shown that CpdA can bind to two glucocorticoid-binding proteins, the cytochrome 
P450c11 enzyme involved in glucocorticoid biosynthesis 
and CBG, the high-affinity glucocorticoid transport 
protein in plasma, we wondered whether perhaps 
CpdA could also interact with the protein involved in 
transducing the glucocorticoid signal, the GR.
Serendipitously, at this stage Prof Janet Hapgood, a 
researcher with extensive signal transduction expertise, 
joined the department and we embarked on a study 
to investigate CpdA’s ability to interact and signal via 
the GR. Not long after, Guy Haegeman25 from Gent 
University in Belgium contacted us and we established a 
very fruitful collaboration on CpdA.
We established that CpdA bound reversibly to the 
GR, albeit at an affinity lower than that of dexamethasone, 
a well-known GR agonist26 (De Bosscher, Vanden 
Berghe, Beck, Van Molle, Hennuyer, Hapgood, Libert, 
Staels, Louw and Haegeman, 2005; Robertson, Allie-
Reid, Vanden Berghe, Visser, Binder, Africander, Vismer, 
De Bosscher, Hapgood, Haegeman and Louw, 2010). In 
addition, CpdA was found to slow the rate of binding of 
radioactively labelled dexamethasone to the GR but to 
have no effect on the dissociation rate of dexamethasone 
from the GR (Robertson et al., 2010). Partial protease 
digestion, a relatively crude technique to compare the 
tertiary27 structure of proteins, indicated that CpdA 
resulted in a conformational change similar to that of 
dexamethasone, which corroborated the binding data 
by indicating that CpdA did indeed interact with the GR 
(De Bosscher et al., 2005).
Binding of a ligand to a receptor does, however, not 
give any indication of the ability of the ligand to signal 
through the receptor, nor does it provide information 
regarding the type of signalling that occurs, in other 
words, whether the ligand is an agonist or an antagonist. 
Having shown that CpdA bound to the GR, we were 
thus curious to know whether it signalled through 
the receptor and investigated this using promoter 
reporter assays28 for transactivation and transrepression 
(refer back to Figure 1). Interestingly, CpdA could not 
transactivate via a glucocorticoid response element 
(GRE, similar to the NRE of Figure 1); however, 
transrepression via a tethering nGRE (similar to the 
tethering nNRE in Figure 1) did occur and was as effective 
as that of the agonist dexamethasone (De Bosscher et al., 
2005). This was very exciting news as at that stage, the 
focus of research for new anti-inflammatory drugs that 
were as effective as glucocorticoids but with a reduced 
side effect profile (remember the double-edged sword 
of glucocorticoids) had shifted to a search for drugs 
that could dissociate the transactivation capacity of the 
GR from its transrepression capability. The reigning 
paradigm29 at that stage consisted of the idea that 
transrepression mediated the positive anti-inflammatory 
action of glucocorticoids while transactivation mediated 
the negative side effect profile of these drugs. Several so-
called dissociated glucocorticoids were being described 
at around this time, many of them with only a slight 
preference for transrepression over transactivation 
while others behaved well in vitro yet failed to 
maintain their dissociated profile in vivo. What made 
CpdA so remarkable was that it displayed complete 
dissociation of transrepression from transactivation. 
In addition, follow-up studies of endogenous genes 
and their protein products indicated that CpdA could 
inhibit the transcription of proinflammatory genes and 
................................
24. It is interesting to note that an increased maternal ratio of cortisol to CBG has been identified as a marker for preterm labour in 
humans.
25. Guy actually saw a poster on CpdA’s interaction with GR presented by a student at a South African Society of Biochemistry and 
Molecular Biology conference at which neither Janet nor I was present as we were both heavily pregnant, Janet with Sammy and I with 
Una. Our collaboration was formalised in two bilateral agreements between South Africa and Belgium and also included researchers from 
the Catholic University of Leuven.
26. In steroid receptor signalling, an agonist will mimic the action of the endogenous hormone (i.e. cortisol for human GR) while an 
antagonist will antagonise the effect of the agonist. Thus an antagonist does not display activity unless in the presence of an agonist. 
27. The primary structure of a protein consists of the sequence of amino acids contained in the protein, the secondary structure refers to 
the general three-dimensional form of local segments of proteins while a protein’s tertiary structure refers to its global geometric shape.
28. Promoter reporter assays are commonly used in signal transduction research as they are simple, quick and specific. They are artificial 
in that the signalling of an artificial construct that contains only the promoter element of interest (i.e. an NRE) coupled to the gene for 
an easily assayed reporter protein (i.e. luciferase) is measured. This is in contrast to an endogenous promoter that may contain several 
promoter signalling elements besides the one being investigated.
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decrease the levels of proinflammatory proteins (i.e. 
interleukin 6) without transactivating genes involved 
in the metabolic side effects of glucocorticoids (i.e. 
tyrosine amino transferase). Furthermore, in a mouse 
model of inflammation, CpdA preformed as well as 
dexamethasone in preventing inflammation without 
giving rise to increased blood glucose levels such as seen 
with dexamethasone (De Bosscher et al., 2005). 
These exciting attributes of CpdA opened up 
glorious prospects for us as researchers, and we set 
out to systematically investigate the signal transduction 
pathway of the GR as regulated by CpdA and to 
compare this with regulation by dexamethasone. We 
have found several similarities and tantalising differences 
between the signal transduction elicited by CpdA and 
that elicited by dexamethasone (De Bosscher et al., 
2005; Robertson et al., 2010; Tanner, Louw, Rombauts, 
Hapgood and Claessens, 2003; Visser, Smith and Louw, 
2010). However, I would like to focus on the attribute 
of CpdA that we now consider to be fundamental to its 
dissociated activity, which is also the attribute that has 
opened up new vistas for us to explore. This attribute 
involves the third step in Figure 1A: GR dimerisation. 
The established model, as illustrated in Figure 1A, 
was that agonists such as dexamethasone resulted in 
dimerisation of the GR, yet we found that CpdA not only 
did not result in dimerisation, it effectively abrogated 
the basal levels of GR dimerisation observed in the 
absence of ligand (Robertson et al., 2010). We were so 
astounded by this finding that we used three separate 
techniques to confirm that indeed CpdA did not result 
in GR dimerisation (Figure 5). We also followed this 
up by comparing the activity of CpdA via the wild-type 
GR (wtGR) with the behaviour of dexamethasone via 
a mutant GR, GRdim, which is unable to dimerise.30 We 
argued that if loss of GR dimerisation was mechanistically 
the essential difference between GR signalling via CpdA 
and signalling via dexamethasone, we should be able 
to recapitulate the critical features of CpdA signalling 
by using dexamethasone and GRdim. We could indeed 
mimic the dissociated behaviour of CpdA via wtGR 
in transrepression and transactivation assays by using 
dexamethasone and GRdim (Robertson et al., 2010).
CpdA has now emerged not only as a possible lead 
compound for future therapeutic applications but also as 
a powerful analytical tool to investigate the implications 
of GR dimerisation in the signal transduction pathway of 
glucocorticoids. 
................................
29. This paradigm has since been found to be an oversimplification as induction of several important anti-inflammatory signals has since 
been shown to be mediated via direct binding of GR to DNA. In science, such modifications of reigning paradigms occur when additional 
information that does not fit the original paradigm becomes available and thus necessitates modification of a paradigm or adoption of an 
entirely new paradigm. 
30. Holger Reichardt, currently at the University of Göttingen in Germany, produced this mutant and has also established a transgenic 
mouse model with GRdim. We plan to collaborate in an investigation of the relevance of GR dimerisation.
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Figure 5: CpdA abrogates dimerisation of the GR. Three experimental techniques were used to confirm that CpdA abolished GR dimerisation.31 
(A) Co-immunoprecipitation of differentially tagged GR: FLAG-tagged GR (mass 96 kDa) and green fluorescent protein (GFP)-tagged GR 
(mass 128.5 kDa) were transfected into cells and treated with either ethanol (control), dexamethasone (DEX) or CpdA. Cellular extracts 
were immunoprecipitated with anti-FLAG antibody that precipitates proteins containing a FLAG-tag (such as the FLAG-tagged GR). Any 
proteins that have associated with the FLAG-tagged GR will be co-immunoprecipitated and may be observed using a second antibody using 
Western blotting.32 In this case, the second antibody used was against the GR. The difference in molecular weight between the FLAG- and 
GFP-tagged GR allows for identification of the two species of GR. The darker band at the GFP-GR position observed with dexamethasone 
indicates that more GFP-tagged GR was immunoprecipitated and therefore greater dimerisation occurred when dexamethasone was 
added. CpdA results in a lighter band indicative of less dimerisation. (B) FRET analysis of differentially tagged GR: cyan fluorescent 
protein (CFP)-tagged GR and yellow fluorescent protein (YFP)-tagged GR were transfected into cells and treated with ethanol (control), 
dexamethasone or CpdA while FRET33 intensity was monitored using a fluorescence microscope. An increase in FRET, as observed with 
dexamethasone, indicates increased dimerisation while the decrease in FRET, as observed with CpdA, indicates abrogation of dimerisation. 
(C) Nuclear translocation of a GR nuclear translocation mutant: wtGR was cotransfected with a c-myc-tagged nuclear translocation mutant 
GR (myGRNL1), which is unable to translocate to the nucleus even in the presence of an agonist ligand. However, if myGRNL1 dimerises 
with wtGR, the nuclear localisation signal present in the wtGR is sufficient for nuclear localisation of the wtGR:myGRNL1 dimer. Localisation 
of myGRNL1 was visualised by indirect immunofluorescence (an anti-c-myc antibody recognises myGRNL1 while a second antibody, which 
contains a florescent tag [green], is directed against the first antibody). Nuclei were visualised with a blue stain. From the micrographs (top: 
control; middle: DEX; bottom: CpdA) and quantification graphs, it is clear that dexamethasone induces nuclear localisation of myGRNL1, 
which implies dimerisation, while CpdA is unable to induce nuclear localisation of myGRNL1 and thus is also unable to induce dimerisation 
(adapted from Robertson et al., 2010).
................................
31. Because GR dimerisation is essentially a homodimerisation, which involves two identical molecules, we tag (small peptide sequences 
genetically grafted onto a recombinant protein) the GR proteins with small molecules that contain attributes that would allow us to track 
and distinguish one GR from another.
32. Western blotting is a widely used analytical technique to identify a specific protein in a mixture. It relies on separation of proteins 
according to their molecular weight and interaction with an antibody against the protein of interest. The correlation of expected molecular 
weight with the presence of a specific antibody-protein interaction confirms the identity of the protein.
33. FRET, an acronym for ‘fluorescence resonance energy transfer’, is a technique that permits investigation of intramolecular interactions 
such as GR dimerisation. If two fluorophore-tagged molecules come into close contact, excitation of the donor fluorophore (e.g. CFP-
tagged GR) results in an energy transfer from the donor fluorophore to the acceptor fluorophore (e.g. YFP-tagged GR), which may be 
measured as a specific emission of fluorescence.
One such investigation, emanating from our laboratory 
in collaboration with Profs Kathy Myburgh and Carine 
Smit,34 focussing on the interplay of the inflammatory 
and stress systems in the liver has yielded some very 
interesting central paradigms regarding the different 
outcomes of CpdA and dexamethasone treatment. The 
liver plays a critical integrative role in inflammation and 
stress by producing the acute-phase proteins (APPs) 
required for swift resolution of inflammation as well as 
by delivering systemic glucose, through gluconeogenesis, 
required to fuel the stress response (often called the 
metabolic response to glucocorticoids). Although the 
repression of inflammatory cytokines by glucocorticoids 
is well studied as being the basis of the anti-inflammatory 
action of glucocorticoids, the effect of inflammatory 
cytokines on glucocorticoid action, especially in the 
periphery, is less well studied. Having shown in vivo 
that the pro-inflammatory cytokine interleukin 6 (IL-6) 
antagonises the effect of glucocorticoids in the liver, 
specifically by limiting autologous down-regulation of 
GR levels35 and by preventing full-blown up-regulation of 
a glucocorticoid-inducible metabolic enzyme in the liver 
(Smith, Wilson, Louw and Myburgh, 2007), we suggested 
that perhaps the brake on glucocorticoid action provided 
by IL-6 in the periphery might limit an overshoot of the 
deleterious endocrine responses of tissues to stress. 
This could act as a second feedback loop complementing 
the well-known feedback loop whereby glucocorticoids 
limit the effects of inflammatory cytokines and in so 
doing exert a finer control over homeostasis than 
would be present without this dual system of reciprocal 
control (Smith et al., 2007). Expansion of the study in 
tissue culture confirmed that glucocorticoids and pro-
inflammatory cytokines generally have divergent effects 
on the GR levels and metabolic enzymes (glucocorticoids 
upregulate while IL-6 down-regulates the GR and 
metabolic enzymes) while their functions are convergent 
on the APPs (both glucocorticoids and IL-6 upregulate 
positive APPs and down-regulate negative APPs) (Visser, 
Smith and Louw, 2010). In contrast, CpdA had effects 
convergent to those of IL-6 on the GR, metabolic 
enzymes and APPs, thus confirming that CpdA would 
result in effective control of inflammation while being 
less likely to lead to glucocorticoid-induced side effects. 
One of the APPs investigated in the above study was 
CBG, which is a negative APP down-regulated during 
the acute-phase response while also being responsible 
for the transport of glucocorticoids in plasma and for 
regulating their bioavailability to tissues (Table 2). The 
molecular signal transduction mechanism whereby 
glucocorticoids down-regulate CBG has now also been 
elucidated by our group and involves tethering of the 
GR to the transcription factor C/EBPβ, a mechanism 
analogous to that in Figure 1C (Verhoog, Allie-Reid, 
Vanden Berghe, Smith, Haegeman, Hapgood and Louw, 
2014).
CpdA is currently available commercially,36 and many 
researchers have used CpdA to investigate aspects 
of steroid receptor action, from prostate cancer to 
osteoporosis (as of March 2015 our publication that first 
discussed the dissociated activity of CpdA [De Bosscher 
et al., 2005] has garnered 124 citations).
NEW GROWTH: THE ROLE OF  
GLUCOCORTICOID RECEPTOR DI-
MERISATION IN GLUCOCORTICOID 
SIGNAL TRANSDUCTION
During the time that we were thinking about the wider implications of CpdA’s ability to abrogate GR 
dimerisation and thus by implication the relevance of GR 
dimerisation in glucocorticoid signalling, we were also 
attempting to reconcile some puzzling binding results 
with CpdA. We found that CpdA’s ability to bind to the 
GR appeared to be influenced by the concentration of 
the GR present while the affinity37 of dexamethasone 
(always included as a control) for the GR also appeared 
to be modulated by GR concentration. This prompted 
us to wonder whether perhaps GR concentration had a 
greater effect on GR signalling than had previously been 
thought.38 A seminal paper presented at our weekly 
laboratory journal club (Cho, Kagan, Blackford, Szapary 
and Simons, 2005) added another clue: this work from 
................................
34. Both are from the Department of Physiological Sciences at Stellenbosch University.
35. Autologous down-regulation of GR by glucocorticoids is thought to be a mechanism whereby glucocorticoids down-regulate the 
concentration of their cognate receptor, thus limiting signalling and preventing overshoot of glucocorticoid action, which would threaten 
homeostasis. 
36. Available from, amongst others, ENZO Life Sciences, product number ALX-550-516, Santa Cruz Biotechnology, product number sc-
221677, and Calbiochem, product number 346110. 
37. The affinity of a ligand for a receptor had always been thought to be an immutable constant and certainly not one that should be affected 
by receptor concentration.
38. At this point, the assumption in steroid receptor signalling was that more receptors would simply result in a greater efficacy in response 
to ligand; in other words, only the amplitude of the response would be affected.
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Table 3: The continuum of GR species potentially available to evaluate loss or gain of 
dimerisation
GR species GR monomers unable 
to dimerise
GR monomers that 
dimerise in the presence 
of agonists





Mammalian cell culture 
cells transfected with GRdim
Mammalian cell culture cells 
transfected with low wtGR 
concentrations
Mammalian cell culture cells 




CpdA Agonists at low levels of 
wtGR
Agonists at high wtGR 
concentrations
GR levels vary among tissues and individuals with, 
for instance, skin cells having 15 times as many GR 
molecules as lung cells. In addition, GR levels are 
altered by physiological and pharmacological effectors 
such as cancer and AIDS that may upregulate GR levels 
or stress and use of glucocorticoid drugs that may 
decrease GR levels. We were thus concerned that the 
levels of GR used in our study should not be supra-
physiological and used three physiologically relevant yet 
statistically different GR concentrations, designated low, 
medium and high. Luckily the physiological range of GR 
concentrations is quite wide (4–900 fmol GR/mg protein 
in healthy individuals and rising as high as 2 777 fmol GR/
mg protein in the skin of AIDS patients), so we had 
sufficient scope for differentiation. 
In our first experiment, we assessed the effect of 
GR concentration on transcription using a promoter 
reporter assay and found that increasing GR 
concentration resulted in a much greater increase in 
efficacy and potency39 of the GR response than we had 
expected (Table 4). Increasing wtGR levels, two-fold 
from low to medium levels and four-fold from low to high 
levels, resulted in an increase in efficacy (Bmax) of four- 
and 12-fold, respectively, and furthermore, a massive 
650- and 2 600-fold increase, respectively, in potency 
(EC50) was observed (Robertson, Rohwer, Hapgood 
and Louw, 2013). In addition, we were intrigued by an 
observation of an increase in basal induction, which we 
attributed to ligand-independent transactivation, arguing 
that perhaps at higher concentrations the GR could 
dimerise and elicit a transcriptional response even in 
the absence of ligand. We established that at medium 
and high GR concentrations, the GR indeed dimerised 
in the absence of ligand, shifting the equilibrium between 
GR monomers and dimers in favour of more dimers 
(from 38% dimers to over 60% dimers at higher GR 
concentrations) (Robertson et al., 2013). Furthermore, 
the laboratory of Stoney Simons Jr., a well-respected researcher investigating the factors that modulate the potency 
and efficacy of the dose-response curve39 of transactivation via the GR, suggested that cooperative ligand binding to 
the GR might occur at high but not at low receptor concentrations. Interestingly, the researchers had not pursued the 
matter nor had they considered that cooperative ligand binding presupposed the presence of at least two binding sites.40 
We then hypothesised that wtGR would display cooperative ligand binding at high concentrations and that perhaps this 
was due to ligand-independent dimerisation. We were thus also very interested in the implications of a loss or gain of 
dimerisation potential and thus employed a continuum of GR species (Table 3).
................................
39. A dose-response curve (whereby the magnitude of the response, for example induction of a gene or expression of a protein, to 
different concentrations of ligand is plotted) may be characterised by two parameters: efficacy (Bmax: maximal response achieved) and 
potency (EC50: the concentration of ligand that elicits a half-maximal response). The Bmax and EC50 are useful parameters to compare the 
signalling between different compounds, such as dexamethasone and CpdA. 
40. Cooperative ligand binding is observed in systems that have multiple binding sites. If the affinity of the binding sites for a ligand 
apparently increases, it is called positive cooperativity while if the affinity decreases, it is called negative cooperativity. In cooperative ligand 
binding, the binding of the first ligand to the receptor changes the affinity of the second ligand binding to the second binding site.
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at high and medium GR concentrations, ligand binding to the GR was shown to be cooperative (Hill slope > 1)41 and 
to display a three-fold increased affinity (Kd) for the ligand. We could recapitulate the findings on an endogenous 
glucocorticoid-responsive gene by also showing the greater-than-expected increase in efficacy and potency, albeit not 
to the same degree as for the artificial system used in promoter reporter studies. Intriguingly, we could also show that 
at medium and high GR concentrations, the GR was already present on the promoter of the gene (i.e. loaded onto the 
DNA), poised to initiate transcription upon arrival of the ligand. To confirm the importance of dimerisation for the 
observed behaviour of the GR at higher concentrations, we utilised GRdim constructs and established that GRdim, unable 
to dimerise to the same extent as wtGR, could not elicit cooperative ligand binding or ligand-independent DNA loading, 
nor could it elicit the same massive shift in transactivation potency as seen with wtGR. We followed up this work by 
investigating the implications of higher GR concentrations and the ability to dimerise on the nuclear import and export 
rate of the GR and concluded that the ability of the GR to dimerise resulted in an increased nuclear import rate and a 
decreased export rate due to an increase in glucocorticoid-dependent GR nuclear foci and that the shorter residence 
time in the nucleus of the GRdim might be a contributing factor to explain the lowered potency of its glucocorticoid 
response (Robertson, Hapgood and Louw, 2013).
Table 4: Summary of dose-response parameters measured at low, medium and high GR 
concentrations 






GR concentration 1 2 4
Maximal efficacy (Bmax) 1 4 12
Potency (EC50) 1 650 2 600
Basal induction 1 4.5 10
Table adapted from Robertson et al., 2013.
To place our results in terms of what we believe, 
the physiological implications may be as follows: In 
tissues with high GR concentrations, such as in skin or 
during certain diseased states, significant formation of 
Figure 6: Model comparing downstream effects at high and low GRwt concentrations. Pathways (A), (B) and (G) denote conditions at 
low GR concentrations. (A) Non-cooperative ligand binding to GR monomers, followed by (B) ligand-dependent dimerisation and (G) 
transactivation. Pathways (C), (D), (E) and (F) denote conditions at high GR concentrations. (C) Ligand-independent dimerisation of the GR, 
followed by either (E) ligand-independent DNA loading and transactivation and/or (D) cooperative ligand binding and (F) transactivation 
with increased potency. Graph insert: Transactivation results simplified as percentage maximal transactivation. Indicated are fold increase 
in ligand-independent transactivation (E) and increase in transactivation efficacy and potency at higher concentrations of GR – difference 
between (G) and (F) (Robertson et al., 2013).
................................
41. A ligand binding curve can provide information regarding the number of receptor molecules in the system and the affinity of the ligand 
for the receptor (Kd) and indicate whether ligand binding is cooperative or not. Non-cooperative binding will have a Hill slope of one while 
positive cooperative ligand binding will have a Hill slope > 1.
preformed ligand-independent dimers will be evident, 
displaying positive cooperative ligand binding and ligand-
independent priming of DNA, poised for the arrival of 
ligand. The tissues would therefore be hypersensitive 
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to glucocorticoids, whether endogenous or exogenous, 
and would exist in a suspended yet partially activated 
state on the promoter DNA, ready to induce a maximal 
transactivative response once exposed to ligand (Figure 
6). In addition, tissues that contain high concentrations 
of GR would respond faster to glucocorticoids due to 
their increased rate of nuclear import and maintain 
nuclear localisation for longer following glucocorticoid 
withdrawal because of their slower rate of nuclear 
export, thus contributing to their enhanced sensitivity 
to glucocorticoids when compared to tissues with low 
GR concentrations. 
FUTURE GROWTH: TOWARDS A 
QUANTITATIVE UNDERSTANDING 
OF THE RELEVANCE OF 
GLUCOCORTICOID RECEPTOR 
DIMERISATION
Dimerisation of the GR is an integral step in glucocorticoid signalling (Figure 1) and has been 
identified as a possible molecular site to target for 
the drug development of dissociated glucocorticoids 
with reduced side effects. Notwithstanding the work 
we have done showing profound effects of gain or 
loss of GR dimerisation on glucocorticoid signalling, 
our understanding of the broader relevance of GR 
dimerisation within the context of glucocorticoid 
signalling remains limited. In other words, we still cannot 
yet fully answer the seemingly trivial question, Why does 
the GR dimerise?
In an attempt to answer this question and in our quest 
to fully understand the implications of GR dimerisation 
for our future work, we propose to construct, with 
the help of Prof Johann Rohwer,42 a realistic kinetic 
mathematical model of GR signal transduction that 
incorporates rate constants obtained under conditions 
that mimic gain or loss of GR dimerisation. To launch the 
project, an initial model of the moiety conserved cycle 
of the GR comprising ligand binding and dimerisation 
will be used (Figure 6, steps A and B versus steps C 
and D). We envision that the quantitative model of 
GR signal transduction would enable us to interpret 
our current and future experimental data within the 
context of understanding the design principles of the 
complex biological network of GR signalling while 
providing quantitative and mechanistic insights that may 
generate novel, experimentally testable hypotheses. 
Meanwhile, we will continue to accrue experimental 
data, both in vitro and in vivo,43 pertaining to the gain or 
loss of GR dimerisation. One aspect of GR signalling 
currently under investigation is the implications of GR 
dimerisation for autologous downregulation of the GR, 
an important issue related to the loss of glucocorticoid 
sensitivity observed in about 30% of patients using long-
term glucocorticoid therapy.
My journey with CpdA has indeed brought us 
unimagined possibilities and glorious prospects; starting 
with grootlamsiekte and the gannabos meandering via 
contraception in rats, cytochrome P450 and CBG to the 
GR and dissociated glucocorticoids, it is now poised on 
the brink of ‘a Great Perhaps’, embarking on the quest 
for obtaining a deep understanding of the relevance and 
significance of varying GR levels, which by implication 
encompasses GR dimerisation, for predicting changed 




42. Prof Rohwer has many years of experience in the mathematical modelling of complex biological systems and will direct the mathematical 
modelling aspects of the project.
43. We have recently received funding to establish a collaboration with Holger Reichart from the University of Göttingen in Germany and 
aim to investigate gain and loss of GR dimerisation by examining tissue samples obtained from wtGR and GRdim mice.
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Cyclopia: More than a cup of tea
About 10 years into my research on CpdA and GR signalling, I was approached by Prof Lizette Joubert44 regarding Cyclopia, better known as honeybush (Figure 7). She was on her own quest of ‘seeking a Great Perhaps’ and kindly 
asked me to join this quest.
Cyclopia, in contrast to the other established herbal 
tea, rooibos tea, was lagging behind in popularity and 
commercial success and was considered to be in need of 
development. Both teas were initially used for medicinal 
purposes; over time, however, this evolved into non-
medicinal use and they are currently consumed as a 
beverage (Joubert, Gelderblom, Louw and de Beer, 
2008). In a quest to expand the potential use of Cyclopia, 
Lizette was characterising the phenolic content of the 
tea and exploring its health-promoting properties for 
possible non-beverage applications. Scrutiny of the 
phenolic composition of Cyclopia coupled with anecdotal 
claims of use in alleviating menopausal symptoms led her 
to the notion that perhaps Cyclopia could be a source of 
phyto-oestrogens.
Phyto-oestrogens are secondary metabolites from 
plants with a structural and functional similarity to the 
endogenous human hormone oestrogen, which suggests 
that they may potentially modulate oestrogen signalling. 
The first step in oestrogen signalling involves binding 
to the ER (Figure 1, Step 1). Two of the ER subtypes, 
namely ER-alpha (ERα) and ER-beta (ERβ), are of clinical 
interest: ERα, as it is the main driver of cell proliferation 
in the breast and endometrium, which could cause 
or enhance the spread of cancer, and ERβ, as it acts 
as a brake, limiting ERα-mediated proliferation. Thus 
compounds that prefer ERβ over ERα are of great 
interest pharmacologically.
Figure 7: Cyclopia or honeybush. Shoots of C. subternata (left) and C. genistoides (right) with distinctive yellow flowers, characteristic of 
Cyclopia species (Louw, Joubert and Visser 2013).
................................
44. Lizette Joubert, from the Agricultural Research Council, works on the indigenous South African herbal teas such as rooibos 
(Aspalathus linearis), honeybush (Cyclopia spp.) and bush tea (Athrixia phylicoides). 
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In 2007 (Verhoog, Joubert and Louw, 2007b) we 
established for the first time that two Cyclopia species, C. 
genistoides and C. subternata, displayed significant phyto-
oestrogenic activity, with one extract from C. genestoides, 
P104, emerging as the most active extract although it 
did not bind more strongly to ERβ than to ERα. We 
had screened both aqueous and methanol extracts from 
each of the four commercially available Cyclopia species, 
C. intermedia, C. subternata, C. genistoides and C. sessiliflora, 
using both fermented and unfermented Cyclopia and 
independent harvestings.45 Generally, the methanol 
extracts from unfermented Cyclopia were more active, 
probably due to the fact that fermentation had been 
shown to reduce polyphenolic content. Of note was the 
great variation in ER-binding capacity found even within a 
species, which led us to conclude that no blanket claims 
regarding the phyto-oestrogenicity of honeybush tea 
could be made. 
Further in-depth studies with the unfermented C. 
genistoides methanol extracts established that despite 
the fact that the P104 extract had an affinity for ERα 
that was about 450-fold higher than its affinity for 
ERβ, the extract was only able to induce an oestrogen 
response element (ERE46)-containing promoter reporter 
construct via ERβ, not via ERα (Verhoog, Joubert and 
Louw, 2007a). In addition, neither the potency nor the 
efficacy was significantly different from that obtained 
with genistein, a well-known phyto-oestrogen obtained 
from soy. Furthermore, although the extracts could 
induce cell proliferation in the well-known breast cancer 
cell line MCF7, the potency of the extract was around 
10 000-fold lower than that obtained for oestrogen and 
besides, the extract could very effectively antagonise the 
proliferation induced by oestrogen (Verhoog, Joubert 
and Louw, 2007a). The binding of extracts to SHBG was 
also evaluated and found to be as effective as genistein in 
displacing oestrogen from SHBG. At this stage, we were 
cautiously optimistic regarding the phyto-oestrogenic 
potential of Cyclopia, especially the disproportionably 
effective activation of the ERβ, an attribute thought to 
be most desirable for the preparation of a nutraceutical47 
for use in HRT.
Several factors have contributed to the renewed 
interest in alternatives for HRT and the identification of 
plants as a possible source of new oestrogen analogues. 
Firstly, some studies on HRT use have identified several 
associated risks, with breast cancer identified as a primary 
adverse outcome, resulting in a concomitant reluctance 
of usage by consumers. Secondly, epidemiological studies 
suggest that an Asian diet rich in soy (which contains 
genistein, a phyto-oestrogen) is protective against 
hot flashes, coronary artery disease and oestrogen-
dependent cancers such as breast and prostate cancer. 
Finally, two attributes of phyto-oestrogens, weak 
oestrogenicity and preference for ERβ, have been linked 
to their beneficial health effects.
Our previous work had been conducted using small 
harvestings obtained for research purposes. Now that 
we were considering Cyclopia extracts for nutraceutical 
applications coupled with the fact that we had established 
that harvestings may differ considerably in terms of 
oestrogenic potential, we focussed our attention on new 
C. genistoides (M7-9) and C. subternata (M6) harvestings 
for which material was available in bulk. In addition, 
we investigated the possibility of enhancing the phyto-
oestrogenicity of our extracts by using a two-dimensional 
approach that explored the use of five solvents of 
differing polarities and two extraction methods while, 
in addition, also investigating extracts that mimicked 
the preparation of a cup of tea, which is how Cyclopia 
is generally consumed (this yielded 22 extracts to be 
examined). Furthermore, we benchmarked our extracts 
against four commercially available preparations.48 The 
study yielded an extract, the sequentially extracted 
M6 methanol extract (SM6Met49), which was 7.2 to 
10.5 times more potent than the closest contender 
(Mfenyana, Joubert and Louw, 2008). In addition, ‘cup-
of-tea’ extracts, prepared by steeping the plant material 
in boiling water, did show appreciable phyto-oestrogenic 
activity. Furthermore, the study established that Cyclopia 
extracts generally had comparable potency and efficacy 
to the commercial extracts and thus had potential as 
marketable phyto-oestrogenic nutraceuticals (Mfenyana, 
Joubert and Louw, 2008).
................................
45. Traditionally, only ‘fermented’ (oxidised to release distinct aroma and flavour) honeybush tea was available to the public, but 
‘unfermented’ (green) tea has recently been introduced to local and international markets. Independent harvestings suggest that the plants 
were harvested from different locations and at different times.
46. Similar to the NRE of Figure 1 but specific for the ER.
47. Non-toxic food extract supplements with health benefits.
48. Phytopause Forte®, a soy isoflavone extract, Promensil®, a red clover isoflavone extract, Remifemin®, a black cohosh extract, and 
Femolene Ultra®, a combination of extracts from several plants including soy, black cohosh, Mexican wild yam and maidenhair tree.
49. SM6Met was produced by sequential extraction of C. subternata (harvesting M6) with dichloromethane, followed by ethyl acetate, 
ethanol and methanol.
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The previous study had not investigated extracts for 
ER isoform specificity, an attribute that is currently a 
hot topic in the search for oestrogenic analogues with 
reduced side effects. Current oestrogens in HRT activate 
both subtypes of ER in all tissues, which is beneficial in 
bone (prevention of osteoporosis) and for hot flashes 
but detrimental in the breast where it promotes cell 
proliferation that increases the risk of cancer. SERMs, 
such as raloxifene and tamoxifen, although not ER 
subtype specific, act as agonists in certain tissues, such as 
bone, increasing bone mineral density, and as antagonists 
in others, such as breast tissue, decreasing the risk of 
breast cancer. However, they are not considered as 
suitable alternatives for HRT as they have been linked 
to an increased risk of venous thromboembolism and 
occurrence of hot flashes and can stimulate endometrial 
growth. It has been suggested that the development of 
ER subtype-specific modulators (SERSMs) could herald 
a new era of HRT in which replacement therapy not 
only alleviates menopausal symptoms but also protects 
against breast and endometrial cancer. On a molecular 
level, such an ideal SERSM50 would have the following 
attributes: it would act as an ERα-selective antagonist and 
an ERβ-selective agonist, selectively downregulate ERα 
but not ERβ protein levels and display anti-inflammatory 
properties (important in preventing postmenopausal 
osteoporosis) (Maximov, Lee and Jordan, 2013).
We thus set out to investigate the ER subtype-specific 
activity of three Cyclopia extracts, P104 (Verhoog, 
Joubert and Louw, 2007a and 2007b), SM6Met (Mfenyana 
et al., 2008) and ‘cup-of-tea’ (Mfenyana et al., 2008), from 
two species, C. genistoides and C. subternata. All three 
extracts displayed ERα antagonism while two extracts 
(P104 and SM6Met) displayed robust ERβ agonism 
(similar to that of 1nM E2) (Visser, Mortimer and Louw, 
2013). In addition, in breast cancer cells, all Cyclopia 
extracts displayed anti-inflammatory action and although 
they weakly induced proliferation, they antagonised E2-
induced breast cancer cell proliferation. We also for the 
first time evaluated the in vivo effects of SM6Met (the only 
extract available in sufficient quantities) in an immature 
rat uterotrophic model51 and found that SM6Met alone 
did not stimulate the growth of rat uteri (a negative side 
effect of the SERM tamoxifen), antagonised E2-induced 
uterine proliferation and delayed vaginal opening (Figure 
8). This was an important milestone as it was for the first 
time established that the phyto-oestrogenic extracts of 
Cyclopia had in vivo biological activity. The combination 
of ERα antagonism and ERβ agonism observed with 
SM6Met might be advantageous for the treatment 
of menopausal symptoms as ERβ agonist activity has 
recently been shown in clinical trials to reduce hot 
flashes and to diminish the postmenopausal surge in 
inflammatory disorders (anti-inflammatory activity was 
also observed with SM6Met in a promoter reporter 
assay) while SM6Met’s ERα antagonist activity has been 
shown to prevent hyperplasia of the uterus, commonly 
associated with unopposed HRT.52 Furthermore, this 
combination of ERα antagonism and ERβ agonism 
observed with SM6Met may be especially relevant for the 
chemoprevention of breast cancer, both with respect 
to the known roles of ER subtypes in breast cancer 
and as ERα antagonism serves as the basis of current 
chemopreventative agents while ERβ-specific agonists 
have recently been identified as having potential for the 
chemoprevention of breast cancer.
Figure 8: Immature rat uterotrophic model. Immature female 
Wistar rats were treated with E2, in the presence and absence 
of SM6Met or ICI 182,780 (an ER antagonist), genistein (a 
well-known phyto-oestrogen), SM6Met and ICI 182,780 (Visser, 
Mortimer and Louw, 2013).
................................
50. On a systemic level, an ideal SERSM would decrease menopausal symptoms such as hot flashes while protecting against breast and 
endometrial cancer as well as menopause-induced osteoporosis, Alzheimer’s disease, stroke and deep vein thrombosis.
51. This is common in vivo assay to evaluate estrogenic activity. As the rat matures, endogenous oestrogen will result in growth of the 
uterus and vaginal opening. In the immature rat, any estrogenic compound will accelerate these features. As the uterus contains mainly 
ERα, the effect is thought to evaluate ERα-specific effects.
52. In women with an intact uterus, unopposed HRT (i.e. replacement of only oestrogen) would result in uterine hyperplasia. Thus 
progestogens, which oppose the proliferative effect of oestrogens in the uterus, are commonly prescribed in conjunction with oestrogen 
for women with an intact uterus.
................................
53. ADME is an abbreviation for ‘absorption, distribution, metabolism and excretion’. All four criteria influence the levels and kinetics of 
exposure of the extract to tissues and thus determine the pharmacological activity of the extract.
54. Prof Günter Vollmer from the Technische Universität Dresden in Germany is an authority on rat breast cancer models.
55. We were appointed at the same time and as the newest members of the department, and at the time the only female academics, often 
commiserated with each other about the difficulty of balancing our teaching loads with our research.
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Having provided several lines of evidence suggesting 
that the Cyclopia extract SM6Met displays many of the 
attributes of an ideal SERSM and thus has potential as 
a chemopreventive and/or chemotherapeutic agent for 
breast cancer, the Cyclopia project is now on the brink of 
its own ‘Great Perhaps’: that perhaps extracts of Cyclopia 
may provide women with a uniquely South African 
alternative to HRT that could moreover reduce the 
risk of breast cancer. This is most pertinent as although 
breast cancer can affect women of all ages, it occurs 
most commonly in women over the age of 50 and thus 
postmenopausal women are not only the group most at 
risk for breast cancer but also the group that would be 
interested in using HRT, whether traditional or in the 
form of phyto-oestrogen supplements. 
Current and future work on the molecular front 
includes evaluation of the effects of SM6Met on ERα 
and ERβ protein levels (one of the attributes of an 
ideal SERSM that is unresolved) and on SHBG (both 
on SHBG levels and its potential to displace E2) while 
confirmation of the hypothesis that the ERα antagonism 
and ERβ agonism of SM6Met would be superior to 
current SERM treatment in breast cancer cell models is 
also in the pipeline. In addition, future development of 
a phyto-oestrogenic nutraceutical necessitates fulfilling 
important prerequisites for the marketing of health 
claims, such as formulation standardisation, which 
comprises identification of the active compound(s) 
and elucidation of the molecular mechanism of action, 
including the ADME53 of the active compound(s). The 
identification of the active compounds in Cyclopia 
extracts conferring the desirable oestrogenic 
attributes is proving quite challenging, and currently 
we are considering the possibility that more than one 
compound may be involved, possibly in a synergistic 
manner. Finally, as in vivo work is the ‘gold standard’ of 
biological research, we, in collaboration with Günter 
Vollmer,54 have embarked on an evaluation of the ability 
of SM6Met to prevent and/or treat breast cancer in a 
rat model of breast cancer. The preliminary results of 
this study are very promising in that they suggest that 
SM6Met may be delaying tumorigenesis of the mammary 
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